Levobetaxolol

Levobetaxolol

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	topical (ophthalmic)
ATC code	none
Pharmacokinetic data
Biological half-life	20 hours
Identifiers
IUPAC name (S)-1-[p-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride
CAS Number	93221-48-8 N
PubChem CID	60657
IUPHAR/BPS	8035
ChemSpider	54669 Y
UNII	75O9XHA4TU
ChEBI	CHEBI:59254 Y
ChEMBL	CHEMBL1201274 N
Chemical and physical data
Formula	C18H29NO3
Molar mass	307.427 g/mol
3D model (JSmol)	Interactive image
SMILES O(CCc1ccc(OC[C@@H](O)CNC(C)C)cc1)CC2CC2
InChI InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1 Y Key:NWIUTZDMDHAVTP-KRWDZBQOSA-N Y
NY (what is this?)

Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is typically marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker).

Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It is indicated for IOP reduction in patients with open-angle glaucoma or ocular hypertension. Levobetaxolol has fewer cardiovascular side effects than other beta blockers.

Levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure.

The drug has been associated with bradycardia and hypertension.